CD40 and neoplasm: Therefore, the effect of mesothelioma-lysate loaded DCs coupled with FGK45 (CD40 agonist) was tested in immune-competent PDAC mice models and the novel approach induced a significant change in the tumor transcriptome including the inhibitory markers on CD8 +T cells and dramatically enhanced patient survival (54).